NJ State Employees Deferred Compensation Plan’s Alexion Pharmaceuticals ALXN Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-9,000	Closed	-$1.65M	–	516
2021 Q2	$1.65M	Sell	9,000 -3,000	-25%	-$515K	0.22%	107
2021 Q1	$1.83M	Hold	12,000	–	–	0.26%	95
2020 Q4	$1.88M	Hold	12,000	–	–	0.29%	88
2020 Q3	$1.37M	Hold	12,000	–	–	0.25%	95
2020 Q2	$1.35M	Hold	12,000	–	–	0.25%	88
2020 Q1	$1.08M	Hold	12,000	–	–	0.25%	98
2019 Q4	$1.3M	Hold	12,000	–	–	0.22%	104
2019 Q3	$1.18M	Hold	12,000	–	–	0.21%	104
2019 Q2	$1.57M	Hold	12,000	–	–	0.28%	88
2019 Q1	$1.62M	Hold	12,000	–	–	0.3%	85
2018 Q4	$1.17M	Hold	12,000	–	–	0.24%	96
2018 Q3	$1.67M	Hold	12,000	–	–	0.28%	84
2018 Q2	$1.49M	Hold	12,000	–	–	0.27%	86
2018 Q1	$1.34M	Hold	12,000	–	–	0.24%	99
2017 Q4	$1.44M	Hold	12,000	–	–	0.25%	95
2017 Q3	$1.68M	Hold	12,000	–	–	0.31%	76
2017 Q2	$1.46M	Hold	12,000	–	–	0.28%	107
2017 Q1	$1.46M	Buy	12,000 +5,000	+71%	+$645K	0.28%	113
2016 Q4	$856K	Hold	7,000	–	–	0.17%	203
2016 Q3	$858K	Hold	7,000	–	–	0.18%	194
2016 Q2	$817K	Buy	+7,000	New	+$993K	0.17%	196

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's ALXN Position: Q3 2021 in Review

NJ State Employees Deferred Compensation Plan sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 9,000 shares — an estimated $1.65M sold.

NJ State Employees Deferred Compensation Plan first reported a position in ALXN in Q2 2016 and held it in 21 quarters. The position peaked at $1.88M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

NJ State Employees Deferred Compensation Plan reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 9,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.65M.
NJ State Employees Deferred Compensation Plan first reported a position in Alexion Pharmaceuticals in Q2 2016 and held it in 21 quarters.
NJ State Employees Deferred Compensation Plan's Alexion Pharmaceuticals position peaked at $1.88M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2021, filed 26 Oct 2021.